Kingsley's new crown and anti-physical test kits are licensed in the United States for recovery plasma screening, helping to improve the effectiveness of recovery plasma therapy

Kingsley Bio (stock code HK01548), the world's leading biotech company, announced on February 7th that it was the world's first kit cPass capable of detecting functional neutrality and antibodies quickly and effectively. Authorized by the U.S. Food and Drug Administration (FDA) Center for Biological Product Evaluation and Research (CBER) for recovery plasma screening, it is the first FDA-mandated testing reagent to specifically detect COVID-19-19 and antibodies without the use of live viruses.
plasma may contain antiviral antibodies and is commonly used in blood transfusion therapy for COVID-19 hospitalized patients to speed recovery.
However, there are differences in successful treatments for recovery plasma, and it is known that recovery plasma containing functionally active antibodies that can meso-COVID-19 (rather than binding antibodies that do not block the virus) may be more effective than low-to-medium or non-renautable plasma.
, the treatment urgently needs new tools to assess its effectiveness.
and cPass? The function and level of antibodies in recovery plasma can be determined before treatment, which will help improve the effectiveness of recovery plasma therapy and help patients recover more quickly.
As the world's first kit capable of rapid and effective detection of functional neutral antibodies, cPass detects neutral antibodies in patient samples without the use of live viruses, using pure proteins that can be performed in most standard laboratories, resulting in results in about an hour.
, traditional methods require the use of living cells and take several days and a high-security environment ("BSL3") to achieve results.
this approval, the cPass kit was CE (European Certification) in Europe and approved by THESA brazil and the Singapore Health Sciences Agency.
the kit was developed by Kingsley and Professor Wang Linfa of duke-Singapore National University School of Medicine.
, Kingsley is working to bring this kit to China to serve the country's efforts to combat the new crown outbreak.
, Kingsley will continue to support the global healthcare community in its fight against COVID-19 with its extensive portfolio of research and development tools and diagnostics.
source: Medical Valley.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" on this website are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here